Lancet[journal] 检索结果

161. Trump vs higher education: stifling American innovation.

作者: The Lancet.
来源: Lancet. 2025年405卷10491期1717页

162. Regulatory asymmetry in Alzheimer's disease care.

作者: Juan Fortea.;Marina Boban.;Sebastiaan Engelborghs.;Kristian Steen Frederiksen.;Jakub Hort.;Sean Kennelly.;Milica Gregoric Kramberger.;Shima Mehrabian.;Domenico Plantone.;Claire Paquet.;Isabel Santana.;Nikolaos Scarmeas.;Eino Solje.;Luiza Spiru.;Stanislav Šutovský.;Everard G B Vijverberg.;Bengt Winblad.;Frank Jessen.
来源: Lancet. 2025年405卷10492期1812-1813页

163. Africa's renaissance amid declining overseas health aid.

作者: Nelson K Sewankambo.;Hossein Akbarialiabad.;Serigne Magueye Gueye.;Sabrina Bakeera-Kitaka.;Judy N Khanyola.;Kiguli-Malwadde Elsie.;Chiratidzo E Ndhlovu.;Bruce Kirenga.;Abigail Kazembe.;Prisca Olabisi Adejumo.;Majid Sadigh.;Mosa Moshabela.
来源: Lancet. 2025年

164. Freezing of USAID: a health crisis for India's transgender community.

作者: Shashwat S Banerjee.;Barnali Goswami Banerjee.
来源: Lancet. 2025年405卷10492期1813-1814页

165. Guatemala's resolution on kidney health: a historic opportunity.

作者: Marcello Tonelli.;Masaomi Nangaku.;Magdalena Machalska.;Agnes Fogo.;Vivekanand Jha.;David Harris.;Adeera Levin.;Giuseppe Remuzzi.
来源: Lancet. 2025年405卷10492期1809-1810页

166. Examining the evidence for IL-2 in amyotrophic lateral sclerosis.

作者: Michael Benatar.;Michael P McDermott.
来源: Lancet. 2025年405卷10492期1793-1795页

167. Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

作者: Gilbert Bensimon.;P Nigel Leigh.;Timothy Tree.;Andrea Malaspina.;Christine Am Payan.;Hang-Phuong Pham.;Pieter Klaassen.;Pamela J Shaw.;Ahmad Al Khleifat.;Maria D M Amador.;Shahram Attarian.;Simon M Bell.;Stéphane Beltran.;Emilien Bernard.;William Camu.;Philippe Corcia.;Jean-Christophe Corvol.;Philippe Couratier.;Véronique Danel.;Rabab Debs.;Claude Desnuelle.;Aikaterini Dimitriou.;John Ealing.;Florence Esselin.;Marie-Céline Fleury.;George H Gorrie.;Aude-Marie Grapperon.;Adèle Hesters.;Raul Juntas-Morales.;Ivan Kolev.;Géraldine Lautrette.;Nadine Le Forestier.;Christopher J McDermott.;Nicolas Pageot.;François Salachas.;Nikhil Sharma.;Marie-Hélène Soriani.;Jemeen Sreedharan.;Juliette Svahn.;Nick Verber.;Annie Verschueren.;Ozlem Yildiz.;Carey M Suehs.;Safaa Saker-Delye.;Claudie Muller.;Christophe Masseguin.;Hana Hajduchova.;Janine Kirby.;Cecilia Garlanda.;Massimo Locati.;Henrik Zetterberg.;Bernard Asselain.;Ammar Al-Chalabi.; .
来源: Lancet. 2025年405卷10492期1837-1850页

Amyotrophic lateral sclerosis (ALS) is a life-threatening disease characterised by progressive loss of motor neurons with few therapeutic options. The MIROCALS study tested the hypothesis that low-dose interleukin-2 (IL-2LD) improves survival and function in ALS.

168. Reducing the burden of chronic kidney disease in the world.

作者: Randall Lou-Meda.;Joaquín Barnoya Pérez.
来源: Lancet. 2025年405卷10492期1810页

169. Nivolumab plus ipilimumab in hepatocellular carcinoma.

作者: Mathew Vithayathil.;Rohini Sharma.
来源: Lancet. 2025年405卷10492期1795-1797页

170. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.

作者: Thomas Yau.;Peter R Galle.;Thomas Decaens.;Bruno Sangro.;Shukui Qin.;Leonardo G da Fonseca.;Hatim Karachiwala.;Jean-Frederic Blanc.;Joong-Won Park.;Edward Gane.;Matthias Pinter.;Ana Matilla Peña.;Masafumi Ikeda.;David Tai.;Armando Santoro.;Gonzalo Pizarro.;Chang-Fang Chiu.;Michael Schenker.;Aiwu He.;Hong Jae Chon.;Joanna Wojcik-Tomaszewska.;Gontran Verset.;Qi Qi Wang.;Caitlyn Stromko.;Jaclyn Neely.;Prianka Singh.;Maria Jesus Jimenez Exposito.;Masatoshi Kudo.; .
来源: Lancet. 2025年405卷10492期1851-1864页

Patients with unresectable hepatocellular carcinoma have a poor prognosis, and treatments with long-term benefits are needed. We report results from the preplanned interim analysis of the CheckMate 9DW trial assessing nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in the first-line setting.

171. Department of Error.

来源: Lancet. 2025年405卷10490期1665页

172. Isotretinoin-associated cervical osteophytosis - Authors' reply.

作者: Kamran Naraghi.;Helena Marzo-Ortega.
来源: Lancet. 2025年405卷10490期1664-1665页

173. Isotretinoin-associated cervical osteophytosis.

作者: Huang Chang-Quan.
来源: Lancet. 2025年405卷10490期1664页

174. Positive RPR and TPLA tests cannot confirm congenital syphilis.

作者: Xin Yu Yang.;Gong Jie Zhang.;Ya Bin Zhou.
来源: Lancet. 2025年405卷10490期1663页

175. Positive RPR and TPLA tests cannot confirm congenital syphilis - Authors' reply.

作者: Tomoaki Hirate.;Kunihiro Shinoda.;Nobuyuki Tetsuka.
来源: Lancet. 2025年405卷10490期1663-1664页

176. The Changing Mindsets Initiative.

作者: Abdul Ghaffar.;Seye Abimbola.;Ren Minghui.;Jesse Uneke.;Rhoda Wanyenze.;Srinath Reddy.
来源: Lancet. 2025年405卷10490期1662页

177. Safety of intranasally administered etripamil: RAPID trial update.

作者: Bruce S Stambler.;A John Camm.;Jonathan P Piccini.;David B Bharucha.;James E Ip.; .
来源: Lancet. 2025年405卷10490期1662-1663页

178. Triple crisis among refugee youth resettled in high-income countries.

作者: Nhial T Tutlam.;Nyabang Buom.;Samuel Kizito.;Salma Abdalla.
来源: Lancet. 2025年405卷10490期1661-1662页

179. Intimate partner violence and ART adherence in Uganda.

作者: Josephine Nabayinda.;Samuel Kizito.;Fred M Ssewamala.;Mary McKay.
来源: Lancet. 2025年405卷10490期1660-1661页

180. 50 years of SSRIs: weighing benefits and harms.

作者: The Lancet.
来源: Lancet. 2025年405卷10490期1641页

结果排序

文献格式

出版时间

出版类型

出版语言